Enanta to present zelicapavir data at IDWeek 2026
Enanta Pharmaceuticals plans to present data on its oral, once-daily N-protein inhibitor zelicapavir, which is in development to treat respiratory syncytial virus.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
5 results loaded, newest first. End of these results.
Enanta to present Phase 2 trial data for RSV drug candidate zelicapavir at IDWeek 2026
Enanta Pharmaceuticals flagged new Phase 2 results for RSV drug candidate zelicapavir, scheduled for presentation at IDWeek 2026. Trial data indicate faster symptom resolution, fewer hospitalizations, lower viral burden versus placebo in high-risk adults. Presentation is set for Oct. 22, 2026, positioning zelicapavir a
Enanta to Present Phase 2 RSV Data at IDWeek 2026
Enanta Pharmaceuticals plans to present Phase 2 data for zelicapavir at IDWeek 2026 on Oct. 22. The data concern symptom resolution, hospitalization and viral load in high-risk adults.
Enanta to Present Zelicapavir Data at IDWeek 2026
Enanta Pharmaceuticals said it will present data for zelicapavir, an oral, once-daily N-protein inhibitor in development for respiratory syncytial virus, at IDWeek 2026.
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once — Daily, N — Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026
For best results when printing this announcement, please click on link below: Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026 Enanta Pharmaceuticals, Inc. ( ) (NASDAQ:ENTA), a clinical stag